HRP Anti-Cytokeratin 5 antibody [EPR1600Y],Abcam,AB303073
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
Target Binding Affinity, Antibody Labelling, IHC-P, WB
Conjugate
HRP
Platform ID
BAB651787665
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Product Specifications
Scientific Background
Specifications
NameHRP Anti-Cytokeratin 5 antibody [EPR1600Y]
Cat. No.AB303073
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationHRP
ApplicationTarget Binding Affinity, Antibody Labelling, IHC-P, WB
ClonalityMonoclonal
Clone NumberEPR1600Y
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only
Scientific Background
Target data Required for the formation of keratin intermediate filaments in the basal epidermis and maintenance of the skin barrier in response to mechanical stress (By similarity). Regulates the recruitment of Langerhans cells to the epidermis, potentially by modulation of the abundance of macrophage chemotactic cytokines, macrophage inflammatory cytokines and CTNND1 localization in keratinocytes (By similarity). See full target information Keratin, type II cytoskeletal 5
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.